PMC:7306567 / 35153-35714
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T179 | 450-453 | Disease | denotes | MSD | http://purl.obolibrary.org/obo/MONDO_0010088 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T224 | 114-117 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T225 | 288-290 | http://www.ebi.ac.uk/efo/EFO_0000265 | denotes | Da |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T237 | 0-2 | Chemical | denotes | OA | http://purl.obolibrary.org/obo/CHEBI_138856 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T257 | 0-561 | Sentence | denotes | OA Cornely is supported by the German Federal Ministry of Research and Education and the European Commission, and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Merck/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical. |